Skip to main content

Table 3 Performance comparison for detection of the EGFR T790M mutation between the Cobas assay, ddPCR, and NGS using plasma from NSCLC patients

From: Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy

EGFR genotype TP and TNa (38 cases with NGS results) Cobas assay using cfDNA (n = 54) ddPCR using cfDNA + exoTNA (n = 54) NGS using cfDNA + exoTNA (n = 38)
Mutant type Wild-type Mutant type Wild-type Mutant type Wild-type
Mutant type 17 (15) 11 6 15 2 14 1
Wild-type 37 (23) 0 37 0 37 0 23
Sensitivity,% (95% CI)   64.7 (63.4–66) 88.2 (86.9–89.5) 93.3 (91.7–94.9)
Specificity, % (95% CI)   100 (98.7–101) 100 (98.7–101) 100 (98.4–102)
Accuracy, % (95% CI)   88.9 (87.6–90.2) 96.3 (95–97.6) 97.4 (95.8–99)
  1. a‘True positive’ was defined as a positive T790M mutation in one or more liquid biopsy platforms among Cobas, ddPCR, and NGS; ‘True negative’ was defined as T790M mutation negative in all tested liquid biopsy platforms
  2. NSCLC non-small cell lung cancer, TP true positive, TN true negative, CI confidence interval